A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HALO-CM
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 07 Jun 2017 According to a Teva Pharmaceuticals media release, results from this trial will be presented at American Headache Society (AHS) Annual Scientific Meeting, and results from this and another trial in episodic migraine will be presented at the Congress of the International Headache Society (IHC) later this year.
    • 07 Jun 2017 This trial has been completed inFinland(End date:2017-04-11) as per European Clinical Trials Database record.
    • 31 May 2017 According to a Teva Pharmaceutical Industries media release, based on the results from the study, Teva plans to submit a Biologics License Application to the U.S. Food and Drug Administration (FDA) for fremanezumab later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top